Newly developed retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Initial clinical trials have revealed substantial reductions in overall mass and advancements in metabolic markers for people with overweight. Researchers believe this unique